Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization

Area of Science:

• Nanotechnology
• Pharmaceutical Sciences
• Drug Delivery

Background:

• Vinpocetine (VIN) is used for chronic cerebral vascular ischemia but has low bioavailability and a short half-life.
• A sustained drug-delivery system is needed to overcome VIN's pharmacokinetic limitations.
• Solid lipid nanoparticles (SLNs) offer a potential platform for targeted and sustained drug delivery.

Purpose of the Study:

• To formulate and characterize Vinpocetine (VIN) loaded solid lipid nanoparticles (SLNs) for brain targeting.
• To investigate the impact of lipids and surfactants on SLN properties and drug release.
• To identify an optimal SLN formulation for sustained VIN delivery to the brain.

Main Methods:

• VIN SLNs were prepared using modified high shear homogenization and ultrasonication.
• Formulations were characterized by entrapment efficiency (EE%), particle size, zeta-potential, and in vitro drug release.
• Different lipids and surfactant combinations were evaluated to optimize SLN characteristics.

Main Results:

• High entrapment efficiencies (83.34%-94.56%) were achieved due to VIN's lipophilic nature.
• Particle sizes ranged from 123 nm to 464 nm, with the optimal formula (F32) around 90 nm.
• The optimized formula (F32) exhibited a zero-order release profile, releasing 72.12% of VIN over 96 hours.

Conclusions:

• The developed VIN-loaded SLNs show potential as a brain-targeted sustained drug delivery system.
• Formula F32, utilizing glyceryl monostearate and a Tween 80/Pluronic F 68 mixture, demonstrated favorable characteristics for brain delivery.
• The study highlights the promise of SLNs for improving the therapeutic efficacy of VIN.